181696-35-5

Usage

Uses

Used in Pharmaceutical Industry:
Valdecoxib IMpurity D is used as a reference standard for the development and validation of analytical methods for the detection and quantification of Valdecoxib and its related substances in pharmaceutical formulations. It helps ensure the quality, purity, and safety of Valdecoxib-containing products.
Used in Research and Development:
Valdecoxib IMpurity D is used as a research tool for studying the metabolism, pharmacokinetics, and pharmacodynamics of Valdecoxib. It aids in understanding the mechanisms of action, efficacy, and safety of Valdecoxib in treating various inflammatory conditions.
Used in Quality Control:
Valdecoxib IMpurity D is used as a quality control material for the assessment of the performance of analytical instruments and methods used in the analysis of Valdecoxib and its impurities. It helps ensure the accuracy, precision, and reliability of the analytical results obtained.

Upstream product

• 37928-17-9 5-methyl-3,4-diphenyl isoxazole 
• 857259-65-5 5-methyl-3,4-diphenyl-5-(pyrrolidin-1-yl)-4,5-dihydroisoxazole 
• 52201-28-2 1-(1-methyl-2-phenyl ethenyl)-pyrrolidine 
• 103-79-7 1-phenyl-acetone 
• 509074-26-4 4-(5-methyl-3-phenylisoxazol-4-yl)benzenesulfonyl chloride 
• 932-90-1 Benzaldoxime 

Downstream Products

• 897927-43-4 4-[(5-methyl-3-phenyl)-4-isoxazolyl]benzenesulfonate sodium salt 
• 181695-72-7 valdecoxib 

Relevant academic research and scientific papers

Preparation method of parecoxib sodium

The invention belongs to the technical field of drug preparation, and specifically relates to a preparation method of parecoxib sodium. The preparation method comprises sulfonation reactions, amination reactions, propionylation reactions, and salt forming reactions. In sulfonation reactions, 5-methyl-3,4-diphenyl isoxazole is taken as the primary raw material and directly carries out reactions with chlorosulfonic acid, after reactions, and the reaction system is poured into water to carry out quenching to obtain suspension of reaction products. All used reagents are common reagents; the preparation method only uses third kind solvents, which are regulated by International Council for Harmonization (ICH) and are harmless for human body; the operation of the preparation method and post treatment is simple, the repeatability is good, the yield is high, and the cost is low. The purity of prepared parecoxib sodium can reach 99.9% or more. The quality of prepared parecoxib sodium is higher than the standards made by a plant that develops parecoxib sodium. The preparation method is suitable for industrial production of pharmaceutical enterprises.

Method for synthesizing parecoxib

The invention discloses a method for synthesizing parecoxib. Widely sourced adenosine is taken as an initial raw material and is subjected to cyclization, amination and amidation sequentially. Fewer steps are adopted, few by-products are obtained, the yield is increased, and the production cost is reduced.

Method for preparing cyclooxygenase-2 inhibitor parecoxib

The invention discloses a method for preparing a cyclooxygenase-2 inhibitor parecoxib. The method comprises the following steps: 1) enabling benzaldoxime and 1-(4-sulfonyl phenyl)propyne to react in an illumination condition in the presence of tri(2-phenylpyridine)iridium (III), triethylamine and magnesium oxide to obtain 5-methyl-3-phenyl-4-(4-sulfonyl phenyl)isoxazole; 2) conducting a contact reaction between 5-methyl-3-phenyl-4-(4-sulfonyl phenyl)isoxazole obtained in the step 1) and thionyl chloride; after the reaction, extracting dichloromethane; directly adding the dichloromethane phase into ammonia water; separating organic phase; washing and concentrating; and recrystallizing with ethanol to obtain valdecoxib; and 3) enabling the valdecoxib obtained in the step 2) to react with propionic anhydride in the presence of triethylamine to obtain parecoxib. The parecoxib preparation method disclosed by the invention has the advantages of simple steps, high yield and simple aftertreatment.

A cyclooxygenase -2 inhibitor handkerchief auspicious past cloth method for the preparation of intermediates (by machine translation)

The invention discloses a cyclooxygenase -2 inhibitor for the preparation of intermediates handkerchief auspicious past cloth, the preparation method comprises the following steps: in diethyla acid iodophenylamino and the presence of potassium iodide, to the 1 [...] phenyl -2 the [...] (4 the phenyl sulfonate [...] ) - 2 the acetyl ethanone and ammonium [...] contact reaction, after the reaction, the organic phase concentrated, water washing, then recrystallized with ethanol, dried to obtain the 5 [...] methyl -3 the [...] phenyl -4 the [...] (4 the phenyl sulfonate [...] ) heteroploid oxazole. The invention method for the preparation of intermediates handkerchief auspicious past cloth of simple steps, mild conditions and high yield. (by machine translation)

Application of [3+2]-cycloaddition in the synthesis of valdecoxib

A large scale synthesis of valdecoxib 1 is described. Our work features potential application of [3+2]-dipolar cycloaddition involving enamine and in situ-generated nitrile oxide derivatives. Dr. Reddy's Laboratories Ltd.

A NOVEL PROCESS FOR PREPARING VALDECOXIB

The present invention relatesto a novel process for making 4-[5-methyl -3-phenylisoxazol-4-yl] benzenesulphonamide

Isoxazole compounds as cyclooxygenase inhibitors

A class of substituted isoxazolyl compounds is described for use in treating cyclooxygenase-2 related disorders. Compounds of particular interest are defined by Formula I STR1 wherein R1, R2, and R3, are described in the specification.

SUBSTITUTED ISOXAZOLES FOR THE TREATMENT OF INFLAMMATION

A class of substituted isoxazolyl compounds is described for use in treating inflammation and inflammation-related disorders. Compounds of particular interest are defined by Formula II wherein R1 is selected from hydroxyl, lower alkyl, carboxyl, lower carboxyalkyl, lower aminocarbonylalkyl, lower alkoxycarbonylalkyl, lower aralkyl, lower alkoxyalkyl, lower aralkoxyalkyl, lower alkylthioalkyl, lower aralkylthioalkyl, lower alkylaminoalkyl, lower aryloxyalkyl, lower arylthioalkyl, lower haloalkyl, lower hydroxylalkyl, cycloalkyl, cycloalkylalkyl, and aralkyl; wherein R3 is selected from cycloalkyl, cycloalkenyl, aryl, and heteroaryl; wherein R3 is optionally substituted at a substitutable position with one or more radicals independently selected from lower alkylsulfinyl, lower alkyl, cyano, carboxyl, lower alkoxycarbonyl, lower haloalkyl, hydroxyl, lower hydroxyalkyl, lower haloalkoxy, amino, lower alkylamino, lower arylamino, lower aminoalkyl, nitro, halo, lower alkoxy, aminosulfonyl, and lower alkylthio; and wherein R4 is selected from lower alkyl, hydroxyl and amino; or a pharmaceutically-acceptable salt thereof